Skip to main content
Article thumbnail
Location of Repository

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

By Shirin Bruderer, Päivi Äänismaa, Marie-Claude Homery, Stephanie Häusler, Kyle Landskroner, Patricia N. Sidharta, Alexander Treiber and Jasper Dingemanse

Abstract

Macitentan is a dual endothelin receptor antagonist under phase 3 investigation in pulmonary arterial hypertension. We investigated the effect of cyclosporine (Cs) and rifampin on the pharmacokinetics of macitentan and its metabolites ACT-132577 and ACT-373898 in healthy male subjects. In addition, in vitro studies were performed to investigate interactions between macitentan and its active metabolite ACT-132577 with human organic anion-transporting polypeptides (OATPs). The clinical study (AC-055-111) was conducted as a two-part, one-sequence, crossover study. Ten subjects in each part received multiple-dose macitentan followed by multiple-dose co-administration of Cs (part A) or rifampin (part B). In the presence of Cs, steady-state area under the plasma concentration–time profiles during a dose interval (AUCτ) for macitentan and ACT-373898 increased 10% and 7%, respectively, and decreased 3% for ACT-132577. Steady-state AUCτ of macitentan and ACT-373898 in the presence of rifampin decreased 79% and 64%, respectively. For ACT-132577, no relevant difference in AUCτ between the two treatments was observed. Macitentan co-administered with Cs or rifampin was well tolerated. The complementary in vitro studies demonstrated no marked differences in uptake rates of macitentan and ACT-132577 between the wild-type and OATP over-expressing cells over the concentration range tested. Concomitant treatment with Cs did not have any clinically relevant effect on the exposure to macitentan or its metabolites, at steady-state. Concomitant treatment with rifampin reduced significantly the exposure to macitentan and its metabolite ACT-373898 at steady-state but did not affect the exposure to the active metabolite ACT-132577 to a clinically relevant extent

Topics: Research Article
Publisher: Springer US
OAI identifier: oai:pubmedcentral.nih.gov:3282010
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2009). Actelion Pharmaceuticals Ltd. Tracleer (bosentan) tablets. United States Food and Drug Administration Drug Product Label
    2. (2011). Allschwil: Actelion Pharmaceuticals Ltd.
    3. and safety of the dual endothelin receptor antagonist macitentan in Japanese and Caucasian healthy subjects. Clin Pharmacol Ther.
    4. (2007). Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampin, and sildenafil. Drug Metab Dispos.
    5. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan.
    6. Consortium. Membrane transporters in drug development.
    7. Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist.
    8. Effects of rifampin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.
    9. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat.
    10. (1992). Endothelin receptor antagonism is protective in in-vivo acute cyclosporine toxicity. Kidney Int.
    11. (2008). Guidance for industry 2008, safety testing of drug metabolites. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research
    12. (2007). Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther.
    13. Interactions of rifamycin SV and rifampin with organic anion uptake systems of human liver.
    14. Investigation of the effect of ketoconazole on the pharmacokinetics of macitentan in healthy male subjects.
    15. Macitentan: entry-into-humans study with a new endothelin receptor antagonist.
    16. Multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist ACT-064992 in healthy human subjects.
    17. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition.
    18. (2003). Pharmacokinetic interactions with rifampin: clinical relevance. Clin Pharmacokinet.
    19. Pharmacology of macitentan, an orally active tissuetargeting dual endothelin receptor antagonist.
    20. Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther.
    21. Renal hemodynamics and pharmaco-kinetics of bosentan with and without CsA.
    22. (1990). Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int.
    23. (2009). summary of product characteristics of Cs.
    24. (2009). summary of product characteristics of rifampin.
    25. Update on rifampin and rifabutin drug interactions.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.